

Press Release

Bangalore, July 27, 2011

Strides Announces Strong Q2 '2011 Financials

Consolidated Financials

Revenue up by 28%, EBITDA up by 11%, PAT up by 39%

Standalone Financials


Revenue up by 68%, EBITDA up by 96%, PAT up by 100+%

Q2 ' 2011	Consolidated	Standalone
Revenue	Rs. 618 Crores (484 Crores in Q2 '10) 28% growth	Rs. 201 Crores (119 Crores in Q2 '10) 68% growth
EBITDA	Rs. 145 Crores (131 Crores in Q2 '10) 11% growth	Rs. 39 Crores (20 Crores in Q2 '10) 96% growth
PAT	Rs. 70 Crores (50 Crores in Q2 '10) 39% growth	Rs. 15 Crores (Loss of 13.6 Crores in Q2 '10) 100+ % growth

(Source: Unaudited results for Q2'2011)

Highlights:

- US FDA approval for Oncology Complex in May 2011. Further on July 26, 2011 – approval received for Gemcitabine, first oncology injectable approval for the US Market. Product to be launched immediately launched through Pfizer
- European Approval for Oral Dosage Facility in Oncology Complex
- Entered into a tie-up with Malaysian Bio-XCELL Ecosystem to establish a customized facility to manufacture biopharmaceuticals and sterile injectables
- Ascent Pharma, Australia - privatisation process completed
- 19 filings and 15 approvals from key regulated markets and 4 filings and 11 approvals from key emerging markets in the quarter
- 3 products approved by USFDA during the quarter (total approvals at 60)
- 7 additional ANDA's commercialized in H1'11 taking the total to 18



A detailed analysis of the results is appended as an attachment to this press release.

“I am extremely pleased with our Q2-11 performance, which is ahead of our guidance run rate with continued momentum driven by scaled business performance in all verticals. With the US FDA approvals for the Steriles and Oncology plant in place, we will continue our focus on more product launches in key markets.” said Arun Kumar, Vice Chairman & Group CEO, Strides Arcolab Limited.

About Strides Arcolab

Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India, that develops and manufactures a wide range of IP-led niche pharmaceutical products with an emphasis on sterile injectables.

The company has 14 manufacturing facilities across 6 countries with presence in more than 75 countries in developed and emerging markets. Manufacturing is ably supported by a 350-scientist strong global R&D Centre located in Bangalore.

Additional information is available at the Company’s website at www.stridesarco.com.

For further information, please contact:

<u>Strides</u> Mr. T.S. Rangan, Group CFO +91 80 6784 0115 <u>Investors:</u> Mr. Kannan. N: +91 98450 54745 Mr Ajay Singh: +91 80 6784 0813	<u>PR Consultancy</u> Corporate Voice/Weber Shandwick Mahesh Nair: +91 98803 76648 maheshn@corvoshandwick.co.in Hiba Kunil: +91 98807 26372 hiba@corvoshandwick.co.in
---	--

